{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:29:13Z","timestamp":1790623753405,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-025-00553-6","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:14:50Z","timestamp":1743304490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["FLT3 inhibition upregulates OCT4\/NANOG to promote maintenance and TKI resistance of FLT3-ITD+ acute myeloid leukemia"],"prefix":"10.1038","volume":"14","author":[{"given":"Qi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6868-7687","authenticated-orcid":false,"given":"Yaming","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"553_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"553_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"553_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18:1061\u201375.","journal-title":"Lancet Oncol"},{"key":"553_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, D\u00f6hner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19:889\u2013903.","journal-title":"Lancet Oncol"},{"key":"553_CR5","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386\u201398.","journal-title":"N Engl J Med"},{"key":"553_CR6","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","volume":"33","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33:2575\u201384.","journal-title":"Leukemia"},{"key":"553_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722\u201331.","journal-title":"Blood"},{"key":"553_CR8","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"553_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.annonc.2022.11.004","volume":"34","author":"A Bazinet","year":"2023","unstructured":"Bazinet A, Kantarjian HM. Moving toward individualized target-based therapies in acute myeloid leukemia. Ann Oncol 2023;34:141\u201351.","journal-title":"Ann Oncol"},{"key":"553_CR10","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"553_CR11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1470-2045(17)30509-0","volume":"18","author":"N Daver","year":"2017","unstructured":"Daver N, Kantarjian H. FLT3 inhibition in acute myeloid leukaemia. Lancet Oncol. 2017;18:988\u20139.","journal-title":"Lancet Oncol"},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.semcancer.2022.10.001","volume":"86","author":"R Kant","year":"2022","unstructured":"Kant R, Manne RK, Anas M, Penugurti V, Chen T, Pan BS, et al. Deregulated transcription factors in cancer cell metabolisms and reprogramming. Semin Cancer Biol. 2022;86:1158\u201374.","journal-title":"Semin Cancer Biol"},{"key":"553_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.cell.2018.01.029","volume":"172","author":"SA Lambert","year":"2018","unstructured":"Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, et al. The human transcription factors. Cell. 2018;172:650\u201365.","journal-title":"Cell"},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1470-2045(19)30787-9","volume":"21","author":"TM Sissung","year":"2020","unstructured":"Sissung TM, Figg WD. Stem cell clinics: risk of proliferation. Lancet Oncol. 2020;21:205\u20136.","journal-title":"Lancet Oncol"},{"key":"553_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature05934","volume":"448","author":"K Okita","year":"2007","unstructured":"Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313\u20137.","journal-title":"Nature"},{"key":"553_CR16","doi-asserted-by":"publisher","first-page":"C709","DOI":"10.1152\/ajpcell.00212.2015","volume":"309","author":"Y-J Wang","year":"2015","unstructured":"Wang Y-J, Herlyn M. The emerging roles of Oct4 in tumor-initiating cells. Am J Physiol Cell Physiol. 2015;309:C709\u2013C718.","journal-title":"Am J Physiol Cell Physiol"},{"key":"553_CR17","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/ijc.28690","volume":"135","author":"LE Iv Santaliz-Ruiz","year":"2014","unstructured":"Iv Santaliz-Ruiz LE, Xie X, Old M, Teknos TN, Pan Q. Emerging role of nanog in tumorigenesis and cancer stem cells. Int J cancer. 2014;135:2741\u20138.","journal-title":"Int J cancer"},{"key":"553_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3349\/ymj.2018.59.1.35","volume":"59","author":"L You","year":"2018","unstructured":"You L, Guo X, Huang Y. Correlation of cancer stem-cell markers OCT4, SOX2, and NANOG with clinicopathological features and prognosis in operative patients with rectal cancer. Yonsei Med J. 2018;59:35\u201342.","journal-title":"Yonsei Med J"},{"key":"553_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/stem.29","volume":"27","author":"CR Jeter","year":"2009","unstructured":"Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 2009;27:993\u20131005.","journal-title":"Stem Cells"},{"key":"553_CR20","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1002\/stem.2007","volume":"33","author":"CR Jeter","year":"2015","unstructured":"Jeter CR, Yang T, Wang J, Chao H-P, Tang DG. Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells. 2015;33:2381\u201390.","journal-title":"Stem Cells"},{"key":"553_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/10245332.2018.1482050","volume":"23","author":"Y Xiang","year":"2018","unstructured":"Xiang Y, Zhou X. Octamer-binding transcription factor 4 correlates with complex karyotype, FLT3-ITD mutation and poorer risk stratification, and predicts unfavourable prognosis in patients with acute myeloid leukaemia. Hematology. 2018;23:721\u20138.","journal-title":"Hematology"},{"key":"553_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12282-012-0357-y","volume":"21","author":"T Nagata","year":"2014","unstructured":"Nagata T, Shimada Y, Sekine S, Hori R, Matsui K, Okumura T, et al. Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer. 2014;21:96\u2013101.","journal-title":"Breast Cancer"},{"key":"553_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","volume":"93","author":"M Port","year":"2014","unstructured":"Port M, B\u00f6ttcher M, Thol F, Ganser A, Schlenk R, Wasem J, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol. 2014;93:1279\u201386.","journal-title":"Ann Hematol"},{"key":"553_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.oraloncology.2010.12.001","volume":"47","author":"CC Yu","year":"2011","unstructured":"Yu CC, Chen YW, Chiou GY, Tsai LL, Huang PI, Chang CY, et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol. 2011;47:202\u201310.","journal-title":"Oral Oncol"},{"key":"553_CR25","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","volume":"116","author":"T Kindler","year":"2010","unstructured":"Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116:5089\u2013102.","journal-title":"Blood"},{"key":"553_CR26","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/leu.2015.147","volume":"29","author":"IK Park","year":"2015","unstructured":"Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29:2382\u20139.","journal-title":"Leukemia"},{"key":"553_CR27","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","volume":"109","author":"O Piloto","year":"2007","unstructured":"Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109:1643\u201352.","journal-title":"Blood"},{"key":"553_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00345-8","volume":"10","author":"CT Yeh","year":"2021","unstructured":"Yeh CT, Chen TT, Satriyo PB, Wang CH, Wu A, Chao TY, et al. Bruton\u2019s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. Oncogenesis. 2021;10:56.","journal-title":"Oncogenesis"},{"key":"553_CR29","first-page":"727","volume":"43","author":"F Hu","year":"2020","unstructured":"Hu F, Li C, Zheng X, Zhang H, Shen Y, Zhou L, et al. Lung adenocarcinoma resistance to therapy with EGFR\u2011tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG. Oncol Rep. 2020;43:727\u201335.","journal-title":"Oncol Rep"},{"key":"553_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275\u201384.","journal-title":"Nat Rev Cancer"},{"key":"553_CR31","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.2741\/e531","volume":"4","author":"B Malik","year":"2012","unstructured":"Malik B, Nie D. Cancer stem cells and resistance to chemo and radiotherapy. Front Biosci. 2012;4:2142\u20139.","journal-title":"Front Biosci"},{"key":"553_CR32","doi-asserted-by":"publisher","first-page":"101042831769225","DOI":"10.1177\/1010428317692253","volume":"39","author":"S Lee","year":"2017","unstructured":"Lee S, Wottrich S, Bonavida B. Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog). Tumour Biol. 2017;39:1010428317692253.","journal-title":"Tumour Biol"},{"key":"553_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13046-016-0359-2","volume":"35","author":"S Kaufhold","year":"2016","unstructured":"Kaufhold S, Garb\u00e1n H, Bonavida B. Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. J Exp Clin Cancer Res. 2016;35:84.","journal-title":"J Exp Clin Cancer Res"},{"key":"553_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.stemcr.2017.02.005","volume":"8","author":"W Blum","year":"2017","unstructured":"Blum W, Pecze L, Felley-Bosco E, Wu L, de Perrot M, Schwaller B. Stem cell factor-based identification and functional properties of in vitro-selected subpopulations of malignant mesothelioma cells. Stem Cell Rep. 2017;8:1005\u201317.","journal-title":"Stem Cell Rep"},{"key":"553_CR35","doi-asserted-by":"publisher","first-page":"36305","DOI":"10.18632\/oncotarget.16750","volume":"8","author":"JM Gwak","year":"2017","unstructured":"Gwak JM, Kim M, Kim HJ, Jang MH, Park SY. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget. 2017;8:36305\u201318.","journal-title":"Oncotarget"},{"key":"553_CR36","doi-asserted-by":"publisher","first-page":"e2637","DOI":"10.1371\/journal.pone.0002637","volume":"3","author":"YC Chen","year":"2008","unstructured":"Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PloS ONE. 2008;3:e2637.","journal-title":"PloS ONE"},{"key":"553_CR37","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s13046-019-1442-2","volume":"38","author":"SC Lai","year":"2019","unstructured":"Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, et al. DNMT3b\/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6\/STAT3 regulation. J Exp Clin Cancer Res. 2019;38:474.","journal-title":"J Exp Clin Cancer Res"},{"key":"553_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/glia.20800","volume":"57","author":"Z Du","year":"2009","unstructured":"Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y, et al. Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia. 2009;57:724\u201333.","journal-title":"Glia"},{"key":"553_CR39","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.7150\/jca.28349","volume":"10","author":"MX Zhang","year":"2019","unstructured":"Zhang MX, Gan W, Jing CY, Zheng SS, Yi Y, Zhang J, et al. High expression of Oct4 and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. J Cancer. 2019;10:1313\u201324.","journal-title":"J Cancer"},{"key":"553_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hep.23692","volume":"52","author":"XQ Wang","year":"2010","unstructured":"Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology. 2010;52:528\u201339.","journal-title":"Hepatology"},{"key":"553_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s13402-014-0168-6","volume":"37","author":"IA Voutsadakis","year":"2014","unstructured":"Voutsadakis IA. The chemosensitivity of testicular germ cell tumors. Cell Oncol. 2014;37:79\u201394.","journal-title":"Cell Oncol"},{"key":"553_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4161\/cbt.9.4.10666","volume":"9","author":"HM Meng","year":"2010","unstructured":"Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 2010;9:295\u2013302.","journal-title":"Cancer Biol Ther"},{"key":"553_CR43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s12032-011-9860-9","volume":"29","author":"T Lin","year":"2012","unstructured":"Lin T, Ding Y-Q, Li J-M. Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma. Med Oncol. 2012;29:878\u201385.","journal-title":"Med Oncol"},{"key":"553_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2013.07.009","volume":"340","author":"Y Lu","year":"2013","unstructured":"Lu Y, Zhu H, Shan H, Lu J, Chang X, Li X, et al. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett. 2013;340:113\u201323.","journal-title":"Cancer Lett"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00553-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:15:16Z","timestamp":1743459316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00553-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1038\/s41389-025-00553-6","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Our study was approved by the Medical Ethics Committee of the First Hospital of Lanzhou University (Approval No.: LDYYLL-2024-422), and animal care and experimental protocols were performed in accordance with the guidelines established by the Medical Laboratory Animal Ethics Committee of Lanzhou University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"7"}}